Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Lutetium‐177‐dotatate ((177)Lu‐dotatate), a form of peptide receptor radionuclide therapy, was approved by the U.S. Food and Drug Administration for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (NETs) in 2018 based on the promising results of...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Zhu, Mojun, Bassam Sonbol, Mohamad, Halfdanarson, Thorvardur, Hobday, Timothy, Ahn, Daniel, Ma, Wen Wee, Bekaii‐Saab, Tanios
格式: Artigo
語言:Inglês
出版: John Wiley & Sons, Inc. 2020
主題:
Brief Communications
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418337/
https://ncbi.nlm.nih.gov/pubmed/32510802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0029
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍